A 42-year-old man came to the hospital presenting chest discomfort and general weakness. He had come to the hospital with the same symptoms 3 months ago and 12 years prior. His laboratory test showed hypokalemia, hypomagnesemia and hypocalciuria. The arterial blood gas analysis showed hypochloremic metabolic alkalosis. He had an ultrasonography guided renal biopsy, the result was normal at light microscopy and immunofluorescence microscopy. However, a special stain for Na-Cl cotransporter was weakly expressed compared with the control. The patient and his family underwent genetic sequencing about the SLC12A3 gene. He had a homozygous mutation in the 179(th) nucleotide of Exon 1 on the SLC12A3 gene (p.Thr60Met) and his parents and sisters were diagnosed as carrier state of Gitelman's syndrome (GS). GS is an inherited tubular disorder which presents mild hypokalemia, hypomagnesemia and hypocalciuria. Since the symptoms and laboratory results are not severe, it can go unnoticed by physicians. Herein we present a family with GS, diagnosed by genetic sequencing.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4949203 | PMC |
| http://dx.doi.org/10.5049/EBP.2016.14.1.16 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gitelman syndrome with diabetes and kidney stones: A case report.
Medicine (Baltimore)
January 2025
The Department of Clinical Laboratory, Zhejiang Hospital, Hangzhou, China.
Rationale: Gitelman syndrome (GS) is a rare hereditary electrolyte disorder caused by mutations in the SLC12A3 gene. There is limited literature on the role of hydrochlorothiazide (HCT) testing and the SLC12A3 single heterozygous mutation in the diagnosis and management of patients with GS. In addition, cases of GS with concomitant kidney stones are rare.
View Article and Find Full Text PDFThe evolving concepts of KS-WNK1 effect on NCC activity.
Am J Physiol Renal Physiol
February 2025
Molecular Physiology Unit, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.
The field of the with-no-lysine kinases (WNKs) regulation of the thiazide-sensitive NaCl cotransporter (NCC) began at the start of the century with the discovery that mutations in two members of the family, WNK1 and WNK4, resulted in a condition known as familial hyperkalemic hypertension (FHHt). Since FHHt is the mirror image of Gitelman's syndrome that is caused by inactivating mutations of the SLC12A3 gene encoding NCC, it was expected that WNKs modulated NCC activity and that the increased function of the cotransporter is the pathophysiological mechanism of FFHt. This turned out to be the case.
View Article and Find Full Text PDFGenetic Etiology Investigation in Treatment-Resistant Nocturnal Enuresis Children: A descriptive study.
Urol J
December 2024
Health Sciences University Umraniye Training and Research Hospital, Department of Medical Genetics, Istanbul, Turkey.
Article Synopsis
- The study aimed to identify genetic factors contributing to treatment-resistant nocturnal enuresis in children who had already undergone various therapies.
- Twenty-one patients aged 5-18 with treatment-resistant enuresis were analyzed using a specialized genetic panel that included 19 genes associated with the condition.
- Results showed that 20 patients had no significant genetic changes, while one patient had a variant in the AQP2 gene, suggesting that nocturnal enuresis is likely influenced by multiple factors rather than a single genetic cause.
Causal effects of gut microbiota on gout and hyperuricemia: insights from genome-wide Mendelian randomization, RNA-sequencing, 16S rRNA sequencing, and metabolomes.
Biosci Rep
November 2024
Medical College, Guangxi University, Nanning 530004, China.
Article Synopsis
- This study explored how gut microbiota (GM) affects the development of gout and hyperuricemia using genetic data and experiments on mice.
- Researchers used advanced statistical methods to predict the impact of GM on gout and identified specific GM taxa linked to the disease, as well as 38 immune cell traits associated with gout.
- The findings revealed that changes in gut microbiome due to dysbiosis were related to alterations in serum metabolites and kidney gene expression, affecting vitamin B6 metabolism and leading to inflammation.
Finerenone as a Novel Treatment for Gitelman Syndrome: A Case Study of a 35-Year-Old Male with Adrenal Mass and Hypokalemia.
Am J Case Rep
November 2024
Department of Endocrinology, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Article Synopsis
- - Gitelman syndrome (GS) is a rare genetic disorder leading to electrolyte imbalances, notably low potassium levels, due to a mutation in the SLC12A3 gene, affecting kidney function.
- - A 35-year-old man with GS and severe hypokalemia was treated with finerenone, a new medication that helps increase potassium levels without the adverse effects commonly seen with other treatments like spironolactone.
- - This case is significant as it represents the first reported use of finerenone for Gitelman syndrome, providing an alternative treatment option for patients unable to tolerate traditional therapies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!